═══════════════════════════ FOR OTHER ORGANIZATIONS
═══════════════════════════
SERVICE BEYOND TRADITIONAL CHANNELS...
Partnership Models and Specialized Use Cases
TITAN™ serves diverse organizations beyond traditional pharma and biotech. From CROs expanding service portfolios to M&A firms conducting due diligence to well-funded academic programs, our platform adapts to unique business models and specialized applications. Explore how TITAN™ can enhance your organization's capabilities and create new value opportunities.
Interested in standard service tiers?
[View Service Tiers & Pricing ]
Looking for traditional pharma solutions?
[Biotech Startups] | [Mid-Size Pharma] | [Large Pharma]
Service Portfolio Expansion:
CROs & CONTRACT ORGANIZATIONS
Differentiated Capabilities for Competitive Advantage
In today's market, traditional toxicology services are becoming commoditized. TITAN™ allows CROs to break the "commodity trap" by offering cutting-edge, multi-modal safety screening that commands premium margins and deepens client reliance. Your pharma and biotech clients increasingly demand faster, more predictive safety screening. TITAN™ enables you to offer cutting-edge capabilities that command premium pricing and strengthen client relationships.
THE CRO OPPORTUNITY:
-
Market Evolution: Clients demand advanced preclinical capabilities; traditional tox services compete primarily on price.
-
Differentiation Imperative: Premium services command higher margins and create "stickier" client relationships.
-
Revenue and Margin Opportunity: * Premium Pricing: TITAN™ services command 25–40% higher margins than standard tox.
-
New Market Access: Serve academic and small biotech clients who need preliminary data before full GLP.
-
Partnership Value: Become the preferred CRO for innovative companies by offering the "Visual Proof" of safety.
-
Business Model Options:
-
White-Label Integration: Offer "Advanced Toxicity Screening" under your own brand. We provide the technical backbone; you maintain the client relationship.
-
Co-Branded Partnership: Leverage Durametrix’s scientific credibility. Jointly develop protocols and co-market "[Your CRO] + TITAN™ Advanced Safety Assessment." Leverage our scientific validation and publications.
-
Referral and Collaboration Model: Direct clients to us for TITAN™ services and specialized imaging needs and receive referral fees while coordinating study integration with your traditional services.
Investment Risk Assessment:
M&A & DUE DILIGENCE
Pipeline Validation for High-Stakes Decisions
High-value acquisitions and licensing decisions often depend on incomplete or sponsor-generated preclinical datasets. TITAN™ provides independent, whole-body toxicity intelligence to help identify hidden liabilities, compare asset-level risk, and strengthen decision-making within compressed diligence timelines.
THE DUE DILIGENCE IMPERATIVE:
You're evaluating a $300M biotech acquisition with 6 lead assets. Management claims they're all "clean." You have 90 days to decide. Traditional GLP studies take too long for your decision timeline. TITAN™ delivers enterprise-grade toxicity intelligence in 12–14 weeks—perfect for investment decision windows.
-
The High-Stakes Reality: Safety liabilities can affect deal value by tens of millions; information asymmetry creates risk.
-
Compare Safety Profiles: Independent validation that identifies "silent" risks that management presentations might overlook.
USE CASE SCENARIOS (Theoretical):
Scenario: Private Equity Biotech Acquisition
"We're evaluating BioTech X for $300M acquisition. We need independent validation of their 6 compounds within our 90-day window."
-
Identified Winners: Confirmed 2 assets with superior safety profiles, justifying the valuation.
-
Risk Mitigation: Identified cardiotoxicity in the lead asset that was masked in traditional H&E reports.
-
Financial Impact: Avoided a $300M capital loss on a flawed acquisition.
-
The Financial Impact: $300M in protected capital and $40M in price-negotiation leverage (Projected ROI: 25,000%+).
RESEARCH PARTNERSHIPS:
ACADEMIC RESEARCH
Well-Funded Programs and Collaborative Partnerships
STRATEGIC ACADEMIC PARTNERSHIPS:
-
Target Programs: Major Medical Centers, NIH Program Grants (P01, U01), and Industry-Academic Collaborations.
-
Academic Value Drivers:
-
Publication Impact: Multi-modal datasets for high-impact journals (Nature, Science, Cell).
-
Grant Differentiation: Cutting-edge methodology strengthens competitive grant applications.
-
Translational Advancement: Deep dive into toxicity mechanisms and biomarker discovery.
-
PARTNERSHIP DEVELOPMENT:
READY TO EXPLORE PARTNERSHIP OPPORTUNITIES?
Custom Business Models for Unique Organizations
PARTNERSHIP DEVELOPMENT PROCESS:
-
Initial Strategy Discussion (45–60 mins): Identify optimal integration approach (white-label, co-branded, referral).
-
Custom Partnership Proposal (1–2 weeks): Detailed business model with revenue sharing and pricing structure.
-
Partnership Implementation (2–4 weeks): Team training, legal agreements, and pilot program launch.
CUSTOM PARTNERSHIP DEVELOPMENT:
Every organization has unique needs. We'll work with you to design the optimal partnership model for your specific situation.
LET'S DISCUSS YOUR ORGANIZATION'S OPPORTUNITIES
1. Strategy Consultation
2. Custom Partnership Proposal
3. Implementation Planning
Questions? Contact Us:
Phone: (414) 465-8654
Email: inquiries@durametrix.com
Our team reviews all inquiries daily. You can expect a response from a technical lead by the next business day.